Adaptimmune gains on early liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $1.73 (19%) to $10.94 on Thursday after reporting that its NY-ESO SPEAR T cell therapy led to three partial responses and one case of stable disease in the first four patients with myxoid/round cell liposarcoma (MRCLS) in a Phase I/II trial. The company touched a 52-week high of $13.41 on Thursday, and closed with a market cap above $1 billion.

The company plans to present the data at an upcoming medical meeting...